JP2016513080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513080A5 JP2016513080A5 JP2015555285A JP2015555285A JP2016513080A5 JP 2016513080 A5 JP2016513080 A5 JP 2016513080A5 JP 2015555285 A JP2015555285 A JP 2015555285A JP 2015555285 A JP2015555285 A JP 2015555285A JP 2016513080 A5 JP2016513080 A5 JP 2016513080A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- construct
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361755968P | 2013-01-23 | 2013-01-23 | |
| US201361755960P | 2013-01-23 | 2013-01-23 | |
| US61/755,960 | 2013-01-23 | ||
| US61/755,968 | 2013-01-23 | ||
| US201361771565P | 2013-03-01 | 2013-03-01 | |
| US201361771560P | 2013-03-01 | 2013-03-01 | |
| US61/771,565 | 2013-03-01 | ||
| US61/771,560 | 2013-03-01 | ||
| PCT/US2014/012831 WO2014116880A1 (en) | 2013-01-23 | 2014-01-23 | Targeting constructs based on natural antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513080A JP2016513080A (ja) | 2016-05-12 |
| JP2016513080A5 true JP2016513080A5 (https=) | 2017-02-23 |
| JP6563815B2 JP6563815B2 (ja) | 2019-08-21 |
Family
ID=51228044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555285A Active JP6563815B2 (ja) | 2013-01-23 | 2014-01-23 | 天然抗体に由来する構築物を標的化すること及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160083469A1 (https=) |
| EP (1) | EP2948480A4 (https=) |
| JP (1) | JP6563815B2 (https=) |
| CN (1) | CN108350086A (https=) |
| AU (3) | AU2014209350B8 (https=) |
| CA (1) | CA2899034A1 (https=) |
| HK (1) | HK1218300A1 (https=) |
| IL (2) | IL240084B (https=) |
| WO (1) | WO2014116880A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200182T1 (hr) | 2014-02-25 | 2020-05-01 | Achillion Pharmaceuticals, Inc. | Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja |
| CN106687123A (zh) * | 2014-06-05 | 2017-05-17 | 科罗拉多州大学评议会 | Map44多肽和基于天然抗体的构建体及其用途 |
| EP3892291A1 (en) * | 2014-08-28 | 2021-10-13 | Tufts University | Compositions, methods and kits for treating complement related disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035362A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| EP3526249A4 (en) * | 2016-10-17 | 2020-07-01 | Musc Foundation for Research Development | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INJURY ASSOCIATED WITH A GRAFT |
| WO2018075474A1 (en) * | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| US20190038623A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
| TWI818919B (zh) * | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| EP3852874A1 (en) * | 2018-09-17 | 2021-07-28 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
| BR112021005506A2 (pt) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | formas mórficas de inibidores de fator complementar d |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| MX2021006930A (es) * | 2018-12-11 | 2021-11-17 | Q32 Bio Inc | Construcciones de proteínas de fusión para enfermedades asociadas al complemento. |
| KR20210104071A (ko) | 2018-12-17 | 2021-08-24 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 표적 투약 |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2021247487A1 (en) * | 2020-06-01 | 2021-12-09 | Medical University Of South Carolina | Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders |
| GB2628281A (en) * | 2022-01-07 | 2024-09-18 | Jumio Corp | Biometric authentication using head-mounted devices |
| CN115963841A (zh) * | 2023-01-16 | 2023-04-14 | 大连海事大学 | 基于改进lvs制导的无人帆船动态事件触发控制方法 |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501725A (ja) * | 2004-06-10 | 2008-01-24 | ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | グリカンに特異的な受容体として機能するインテグリンを介したグリコシルホスファチジルイノシトールグリカンシグナル伝達 |
| WO2007112403A2 (en) * | 2006-03-27 | 2007-10-04 | The Regents Of The University Of Colorado | Prevention and treatment of ischemia-reperfusion injury |
| BRPI0812767A2 (pt) * | 2007-06-07 | 2014-12-02 | Genentech Inc | Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento |
| CN101235089A (zh) * | 2008-03-04 | 2008-08-06 | 张秀茹 | 抗β2GPI基因工程Fab抗体 |
| MX2012005151A (es) * | 2009-11-05 | 2012-08-23 | Federico Ii University Of Naples | Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular. |
| US9815890B2 (en) * | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
-
2014
- 2014-01-23 AU AU2014209350A patent/AU2014209350B8/en active Active
- 2014-01-23 HK HK16106277.3A patent/HK1218300A1/zh unknown
- 2014-01-23 CN CN201480017698.6A patent/CN108350086A/zh active Pending
- 2014-01-23 WO PCT/US2014/012831 patent/WO2014116880A1/en not_active Ceased
- 2014-01-23 JP JP2015555285A patent/JP6563815B2/ja active Active
- 2014-01-23 EP EP14742889.0A patent/EP2948480A4/en not_active Withdrawn
- 2014-01-23 CA CA2899034A patent/CA2899034A1/en active Pending
-
2015
- 2015-07-22 IL IL240084A patent/IL240084B/en active IP Right Grant
- 2015-07-23 US US14/807,521 patent/US20160083469A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201826A patent/AU2019201826B2/en active Active
-
2021
- 2021-03-15 IL IL281498A patent/IL281498A/en unknown
- 2021-04-12 US US17/228,279 patent/US20210388080A1/en not_active Abandoned
- 2021-09-14 AU AU2021232692A patent/AU2021232692A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513080A5 (https=) | ||
| Dong et al. | Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR) | |
| Shin et al. | Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy | |
| JP6670275B2 (ja) | 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体 | |
| Marabelle et al. | Depleting tumor-specific Tregs at a single site eradicates disseminated tumors | |
| JP7015820B2 (ja) | 薬物としての使用のための抗ｃｄ４５ｒｃ抗体 | |
| Elvington et al. | Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice | |
| WO2015037005A1 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
| JP7271532B2 (ja) | 生物学的結合分子 | |
| EA028988B1 (ru) | Способ in vitro анализа культуры генетически модифицированных т-клеток для детекции загрязнения | |
| CN104017067A (zh) | T细胞受体 | |
| CN109863402A (zh) | 基于β2-糖蛋白1水平的用巴维昔单抗治疗癌症的方法和其测定 | |
| US20200397855A1 (en) | Modulation of pla2-g1b in therapy | |
| JP7796160B2 (ja) | 生物学的結合分子 | |
| BR112021008795A2 (pt) | Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos | |
| AU2019264673A1 (en) | Vaccine compositions and methods for restoring NKG2D pathway function against cancers | |
| ES2811527T3 (es) | Composiciones farmacéuticas que contienen una leucocidina E mutada | |
| WO2020033923A1 (en) | Antigen binding agents that bind cd277 and uses thereof | |
| Cardone et al. | A novel role for CD46 in wound repair | |
| CN116323657A (zh) | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 | |
| CN103298835A (zh) | 通过icam-3抑制剂抑制单核细胞的聚集的方法 | |
| EP4499687A1 (en) | Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor | |
| US20230355672A1 (en) | Humanized antigen binding units for targeting osteosarcoma cells | |
| US12053505B2 (en) | Hsp70 based combination therapy | |
| CN103214555A (zh) | 介导应激反应的肽抑制剂 |